Volume 10, Issue 5, Pages (May 1999)

Slides:



Advertisements
Similar presentations
Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,
Advertisements

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C
Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes by Diana Y. Chen, Arumugam Balamurugan,
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells  Faith M. Young, Andrew.
Volume 6, Issue 4, Pages (April 1997)
Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer.
Volume 40, Issue 1, Pages (January 2014)
Antigen-Specific CD8 T Cells Can Eliminate Antigen-Bearing Keratinocytes with Clonogenic Potential via an IFN-γ-Dependent Mechanism  Rachel L. De Kluyver,
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.
Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
Volume 9, Issue 4, Pages (October 1998)
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
Marc Hertz, David Nemazee  Immunity 
David Voehringer, Kanade Shinkai, Richard M Locksley  Immunity 
Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell Apoptosis
Volume 45, Issue 2, Pages (August 2016)
Volume 5, Issue 5, Pages (November 1996)
Volume 3, Issue 5, Pages (November 2014)
Volume 25, Issue 3, Pages (March 2017)
Ananda W Goldrath, Michael J Bevan  Immunity 
Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses
Mark H Kaplan, Ulrike Schindler, Stephen T Smiley, Michael J Grusby 
Volume 15, Issue 6, Pages (December 2001)
IKKβ Is Essential for Protecting T Cells from TNFα-Induced Apoptosis
Volume 31, Issue 1, Pages (July 2009)
Volume 18, Issue 3, Pages (March 2003)
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.
CD22 is a negative regulator of B-cell receptor signalling
Volume 33, Issue 1, Pages (July 2010)
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
Volume 28, Issue 3, Pages (March 2008)
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Down-Regulation of IL-4 Gene Transcription and Control of Th2 Cell Differentiation by a Mechanism Involving NFAT1  Alexander Kiani, João P.B Viola, Andrew.
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Volume 27, Issue 4, Pages (October 2007)
Stanford L Peng, Andrea J Gerth, Ann M Ranger, Laurie H Glimcher 
Volume 22, Issue 3, Pages (March 2005)
Volume 43, Issue 2, Pages (August 2015)
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Volume 40, Issue 1, Pages (January 2014)
Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses  Axel Kallies, Annie Xin, Gabrielle T.
Volume 27, Issue 2, Pages (August 2007)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Volume 38, Issue 3, Pages (March 2013)
Fateh Ouaaz, Joseph Arron, Ye Zheng, Yongwon Choi, Amer A Beg  Immunity 
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:
Volume 26, Issue 4, Pages (April 2007)
LAT Links the Pre-BCR to Calcium Signaling
Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.
Volume 7, Issue 2, Pages (August 1997)
David Voehringer, Kanade Shinkai, Richard M Locksley  Immunity 
Volume 28, Issue 5, Pages (May 2008)
Volume 9, Issue 5, Pages (November 1998)
Volume 23, Issue 4, Pages (October 2005)
Volume 26, Issue 6, Pages (June 2007)
by Gonghua Huang, Yanyan Wang, Peter Vogel, and Hongbo Chi
Volume 7, Issue 6, Pages (June 2014)
Volume 37, Issue 2, Pages (August 2012)
Volume 10, Issue 5, Pages (February 2015)
Volume 25, Issue 4, Pages (October 2006)
Presentation transcript:

Volume 10, Issue 5, Pages 595-605 (May 1999) Granzyme A Initiates an Alternative Pathway for Granule-Mediated Apoptosis  Sujan Shresta, Timothy A Graubert, Dori A Thomas, Sofia Z Raptis, Timothy J Ley  Immunity  Volume 10, Issue 5, Pages 595-605 (May 1999) DOI: 10.1016/S1074-7613(00)80059-X

Figure 1 Lack of GzmA or GzmB Protein in Cytotoxic Lymphocytes Derived from GzmA−/− × GzmB−/− Mice Whole-cell extracts were prepared from 1 × 106 LAK cells derived from wild-type (WT), gzmA−/− (A−/−), gzmB−/− (B−/−), gzmA−/− × gzmB−/− (AB−/−), and perforin−/− (P−/−) mice. Recombinant gzmA (MA) (0.2 μg) and gzmB (MB) (0.1 μg) were prepared from supernatants of P. pastoris cultures. Proteins were analyzed via Western blotting using a previously described (Shresta et al. 1995) rabbit anti-murine gzmB antiserum (B) and a rabbit anti-mouse gzmA antiserum (A). Samples in both panels were prepared using denaturing conditions; therefore, both gzmA and gzmB monomers recognized by these antisera migrated at approximately 30 kDa. The position of gzmA is shown by the arrow in (A), and the position of gzmB is shown by the arrow in (B). The heterogenous bands represent different glycosylated forms of these enzymes. Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)

Figure 2 Normal Proliferation and Activation of Cytotoxic Lymphocytes Derived from GzmA−/− × GzmB−/− Splenocytes Day 5 MLR cells (A) and high-dose IL-2-stimulated LAK cells (panel B) derived from wild-type (WT), gzmA−/− × gzmB−/− (AB−/−), and perforin−/− (P−/−) mice were analyzed by flow cytometry. The expression profiles of cells stained with FITC-labeled monoclonal antibodies specific for mouse CD3, CD4, CD8, CD16, PE-labeled NK1.1 (filled histograms) were overlaid with background fluorescence of cells stained with isotype control antibodies (open histograms). The percentages of cells within the gated windows was similar for all mice. Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)

Figure 3 Normal Expression and Activity of Perforin in GzmA−/− × GzmB−/− LAK Cells (A) LAK cell extracts (50 μg) derived from wild-type (WT), gzmA−/− × gzmB−/− (AB−/−), and perforin−/− (P−/−) mice were analyzed by Western blotting. The rat monoclonal antibody directed against mouse perforin detected similar amounts of the 60 kDa perforin protein in WT and AB−/− samples. The position of correctly processed perforin is shown by the arrow. The absence of perforin in the P−/− lane confirmed the specificity of this antibody. (B) Wild-type (WT), gzmA−/− × gzmB−/− (AB−/−), and perforin−/− (P−/−) LAK cell extracts were assayed for hemolytic activity against sheep red blood cell membranes. The amount of hemoglobin released into the red cell supernatants was spectrophotometrically measured at 405 nM. OD405 values (y-axis) were plotted against increasing amounts of LAK cell extracts (x-axis). Similar results were obtained in four independent experiments. Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)

Figure 4 Cytotoxic Activity of GzmA−/− × GzmB−/− MLR Cells In vitro cytotoxicity of allospecific (H-2b anti-H-2d) MLR cells from wild-type (WT), gzmA−/− × gzmB−/− (AB−/−), and perforin−/− (P−/−) mice was tested against the allogeneic (H-2d) TA3 target cells at increasing E:T ratios (3.75:1 to 30:1; T = 104 cells) after 2 hr (top panels) and 8 hr (bottom panels) of incubation of effector with target cells. Data are presented as mean ± SEM of duplicate samples. The SEMs for most of the data points are very small and are contained within the symbols. This experiment is representative of ten experiments with similar results. Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)

Figure 5 Partial Reconstitution of the Early Target Cell DNA Fragmentation Pathway in the GzmA−/− × GzmB Cluster−/− LAK Cells by Recombinant GzmB (A) Total cell extracts from fixed numbers of wild-type LAK cells (WT) and known amounts of recombinant gzmA (MA) and gzmB (MB) were analyzed by Western blotting using rabbit antisera against mouse gzmA (left panel) and mouse gzmB (right panel). (B) A 2 hr 125IUdR release assay was performed using 3.0 × 105 LAK cells derived from wild-type (WT), gzmA−/− × gzmB−/− (AB−/−), and perforin−/− (P−/−) mice and 104 YAC1 targets (E:T ratio = 30:1; incubation time = 2 hr). Recombinant mature gzmA (MA) and/or mature gzmB (MB) were added into each mixture of effector and target cells. Three different amounts (0.5, 1.0, and 2.0 μg) of each recombinant enzyme were used. Data are represented as mean ± SEM of duplicate samples. Similar results were obtained in five separate experiments. Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)

Figure 6 The Phenotypes of GzmA−/− × GzmB−/− and Perforin−/− CD8+ Effector Cells Are Similar in an Acute Graft versus Host Disease Model (A) Phenotype of CD8+ T cell effectors from mice deficient for gzmA or gzmB. Bm1 × 129/SvJ recipient mice were lethally irradiated and were then reconstituted with 2 × 106 syngeneic bone marrow cells mixed with 1 × 106 class I–mismatched CD8+ T cells from wild-type (WT), perforin−/− (P−/−), gzmA−/− (A−/−), or gzmB cluster−/− (B−/−) mice. The Kaplan-Meier plot demonstrates that survival from graft-versus-host disease was similar when gzmA−/− CD8+ T cells (n = 8) were infused, as compared to wild-type CD8+ T cells (n = 7). Survival was significantly prolonged when gzmB cluster−/− CD8+ T cells were used (n = 16) (p < 0.01). When perforin−/− CD8+ T cells were used (n = 15), survival was indistinguishable from control transplants using syngeneic marrow without T cells (n = 4). Data for this curve were pooled from three independent experiments, each of which had a similar outcome. The results for the perforin−/− and gzmB−/− mice have been previously published (Graubert et al. 1997) and are shown for comparison. (B) Phenotype of CD8+ T cell effectors from gzmA−/− × gzmB−/− versus perforin−/− mice. Class I–mismatched transplants were performed as described in (A), except that 1.5 × 105 CD8+ cells were infused. The Kaplan-Meier plot shows that ∼75% of recipients reconstituted with CD8+ T cells from either gzmA−/− × gzmB−/− (n = 11) or perforin−/− (n = 11) mice survived. As expected, all recipients with wild-type CD8+ T cell donors (n = 11) died. Data for this curve were pooled from three independent experiments, each of which had a similar outcome. Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)

Figure 7 A Model for the GzmA and GzmB Pathways This model suggests that the gzmA pathway is independent from gzmB, even though these pathways could potentially converge on common substrates (indicated by overlapping circles). The gzmA pathway induces target cell apoptosis slowly, either because this enzyme is kinetically slow (indicated by the corkscrew) or because it acts through multiple substrates before the apoptotic substrates are reached (indicated by the multiple arrow pathway). Regardless, the gzmA pathway cannot be detected unless the gzmB pathway is inactivated, either by a loss-of-function mutation in the effector cell (e.g., gzmB−/− mice) or by inhibiting the activity of gzmB in the target cell. As an example, the poxvirus crmA gene encodes a serine proteinase inhibitor (serpin) that interacts with and inhibits the activities of apoptotic caspases and gzmB. Under these circumstances, gzmA may still be able to kill the target cell via an independent apoptotic mechanism (see Discussion for details). Immunity 1999 10, 595-605DOI: (10.1016/S1074-7613(00)80059-X)